Stefano De Pietro
University of Pisa
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stefano De Pietro.
Renal Failure | 2001
Vincenzo Panichi; Massimiliano Migliori; Stefano De Pietro; Daniele Taccola; Bianchi Am; Maria Norpoth; Maria Rita Metelli; Luca Giovannini; Ciro Tetta; Roberto Palla
Base-line serum levels of plasma C-reactive protein (CRP) are predictive of future myocardial infarction and sudden cardiac death in apparently healthy subjects, suggesting the hypothesis that chronic inflammation might be important in the pathogenesis of atherothrombosis. CRP production is mediated by several inflammatory mediators: interleukin 6 (IL-6) is currently felt to be the major cytokine influencing the acute phase response. CRP and other acute phase proteins are elevated in dialysis patients and cardiovascular diseases represent the single largest cause of mortality in chronic renal failure patients. Little information is available, however regarding CRP and IL-6 plasma levels in pre-dialysis renal failure. Plasma CRP was determined by a modification of the laser nephelometry technique; IL-6 by immunoassay (RD System); and fibrinogen, serum albumin, cholesterol, triglycerides, hematocrit, white blood cell count, erythrocytic sedimentation rate (ESR) and urinary protein levels by standard laboratory techniques. Results were obtained in 102 chronic pre-dialysis patients whose mean age was 53 ± 5.8 years with a mean creatinine clearance (CCr) of 52 ± 37 mL/min). CRP was greater than 5 mg/L in 25% of the global population. CRP and IL-6 were 4.0 ± 4.6 mg/L and 5.8 ± 5.6 pg/mL, respectively and were not significantly correlated (r = 0.11, p = n.s.). CRP and IL-6 were however related with renal function (CRP versus CCr r = −0.40 p < 0.001; IL-6 versus CCr r = −0.45; p < 0.001). When patients were divided in two groups according to renal function, CRP resulted 7.4 ± 6.3 mg/L in the group of patients with a CCr lower than 20 mL/min (n = 32) and 2.76 ± 4.35 in the group of patients with a CCr higher than 20mL/min (n = 70) (p < 0.0001). CRP and IL-6 were positively related with ESR (r = 0.32 and 0.46 respectively). Serum albumin levels were not significantly different in the two groups of patients (3.2 ± 0.4 versus 3.0 ± 0.5 g/dL). CRP and serum albumin were not significantly related (r = 0.17). CRP and IL-6 correlated positively with ESR (r = 0.32 and 0.46 respectively). In pre-dialysis patients we have demonstrated an increase in both CRP and IL-6 that occurs as renal function decreases. These data provided evidence of the activation – even in the predialysis phase of renal failure – of mechanisms known to contribute to the enhanced cardiovascular morbidity and mortality of the uremic syndrome.
Blood Purification | 2000
Vincenzo Panichi; Massimiliano Migliori; Stefano De Pietro; Daniele Taccola; Bianchi Am; Maria Norpoth; Luca Giovannini; Roberto Palla; Ciro Tetta
Cardiovascular complications caused by an accelerated atherosclerotic disease represent the largest single cause of mortality in chronic renal failure patients. The rapidly developing atherosclerosis of the uremic syndrome appears to be caused by a synergism of different mechanisms, such as malnutrition, oxidative stress and genetic factors. Recent studies provide evidence that chronic inflammation plays an important role in the pathogenesis of cardiovascular diseases. Elevated serum levels of plasma C-reactive protein (CRP) are associated with an increased risk of experiencing myocardial infarction and sudden cardiac death in apparently healthy subjects. Several recently published papers have confirmed this strong association between CRP and the extent and severity of the atherosclerotic processes. In patients affected by predialytic renal failure, increased levels of CRP and interleukin (IL)-6 were recorded in 25% of our population; CRP and IL-6 were inversely related with renal function. These data suggest the activation – even in the predialytic phase of renal failure – of mechanisms known to contribute to the enhanced cardiovascular morbidity and mortality of the uremic syndrome. In recent years we have investigated the hypothesis that the chronic inflammatory state of the uremic patient could at least in part be due to the dialytic technique. We provide evidence suggesting that the increase of CRP in stable dialytic patients may be due to the stimulation of monocyte/macrophage by backfiltration of dialysate contaminants.
Blood Purification | 2016
Giordano Fumagalli; Stefano De Pietro; Massimiliano Migliori; Francesco Paolo Ferrandello; Fabio Trovato; Carlo Donadio; Vincenzo Panichi
Background: Optimizing vascular access outcomes is still a challenge, since 30-60% of arteriovenous fistulas fail or do not mature and catheters are widely used in contemporary patients. Methods: This study reports on strategies and outcomes in a single center in which access planning, surgery and maintenance are managed by a team of nephrologists. We retrospectively analyzed 305 fistulas and 61 grafts created in 270 consecutive patients between 2002 and 2013. Results: The percentage of patients receiving a fistula or graft who initiated hemodialysis with a mature access was 68.6%. Among prevalent patients, 71.7% used a fistula, 15.7% a graft and 12.6% a catheter. Rates of primary failure and revision before cannulation were 14.4 and 1.6% for fistulas vs. 4.9 and 3.3% for grafts. After maturation, complications (1.040 vs. 0.188 per patient-year (py)) and interventions (0.743 vs. 0.066 per py) were greater for grafts than for fistulas (p < 0.001). Secondary patency did not significantly differ between grafts and fistulas (median survival 34.8 vs. 57.3 months, p = 0.36), unless primary failures were excluded from Kaplan-Meier analysis (median survival 34.9 vs. 70.9 months, p = 0.03). Conclusions: High fistula prevalence, low access-related morbidity and catheter dependence were achieved using individualized strategies, including mid-forearm or perforating vein fistula creation and selective graft placement in high risk patients. Direct involvement of nephrologists throughout all steps of access care can improve access outcomes, by promoting a patient-centered approach.
Blood Purification | 1996
Vincenzo Panichi; Bianchi Am; B Andreini; Leonardo Casarosa; Massimiliano Migliori; Stefano De Pietro; M Ferdeghini; Roberto Palla
Hemofiltration (HF) induces a significant reduction in parathormone (PTH). This effect is related not only to the convective removal of PTH molecules but also to the biological suppression of parathyroid glands by plasma-ionized calcium (iCa) increase. The acute inhibitory effect on parathyroid gland activity, ionized calcium mass balance, phosphate kinetics and intact PTH (PTHi) dialytic removal during post-dilution polyamide HF were studied in 31 chronic uremic patients. HF ensures good phosphate removal (from 2.54 +/- 1.19 to 1.27 +/- 0.35 mEq/l; p < 0.01), a positive iCa mass balance (8 +/- 4 mmol/session) with a iCa plasma increase and negligible convective PTHi removal (9 +/- 2 pg/ml). Study of the PTHi profile during HF characterized two different parathyroid responses: 26/31 patients showed a physiological parathyroid gland response to the iCa increase (from 1.17 +/- 0.09 to 1.42 +/- 0.07 mmol/l; p = 0.002) with a significant PTHi decrease (from 123 +/- 111 to 35 +/- 28 pg/ml; p = 0.01) and a maximal PTH inhibition of 88%. In 5 patients, with more severe hyperparathyroidism, in spite of a comparable increase in iCa (from 1.28 +/- 0.12 to 1.46 +/- 0.08 mmol/l; p = 0.02), this physiological calcium-PTHi feedback was lost, revealing an autonomization of the gland (maximal inhibition of 45%). In our experience, study of the PTHi profile during a single HF session may represent a clinical test for the functional exploration of parathyroid glands, suggesting future (medical or surgical) clinical strategy.
Kidney International | 2000
Vincenzo Panichi; Massimiliano Migliori; Stefano De Pietro; Daniele Taccola; B Andreini; Maria Rita Metelli; Luca Giovannini; Roberto Palla
Kidney International | 1998
Vincenzo Panichi; Stefano De Pietro; B Andreini; Bianchi Am; Massimiliano Migliori; Daniele Taccola; Luca Giovannini; C. Tetta; Roberto Palla
Nephrology Dialysis Transplantation | 1999
Vitantonio Di Bello; Vincenzo Panichi; Roberto Pedrinelli; D Giorgi; M. Bianchi; A Bertini; Daniele Taccola; Stefano De Pietro; E Talini; Marco Paterni; C. Giusti
Nephrology Dialysis Transplantation | 2017
Giordano Fumagalli; Stefano De Pietro; Massimiliano Migliori; Vincenzo Panichi
Blood Purification | 2016
Mathini Jayaballa; Bhadran Bose; Muralikrishna Gangadharan Komala; Eddy Ronald Fischer; John Taper; Kamal Sud; Muyao Ye; Yinghong Liu; Letian Zhou; Chang Wang; Xiao Fu; Youming Peng; Hong Liu; Gioacchino Li Cavoli; Onofrio Schillaci; Franca Servillo; Carmela Zagarrigo; Mattia Palmeri; Ugo Rotolo; Tancredi Vincenzo Li Cavoli; An Li; Wenxiong Li; Fengtong Hao; Haishi Wang; Claudio Ronco; Chiara Levante; Rui Su; Yao Rao; Xiaomin Shen; Junna Zhu
Nephrology Dialysis Transplantation | 2015
Stefano De Pietro; Paolo Francesco Ferrandello; Massimiliano Migliori; Alessia Scatena; Ilaria Cipollini; Giordano Fumagalli; Mauro Aloisi; Vincenzo Panichi